Stable Analogs of CYP450 Lipid Metabolites and Inhibitors of Soluble Epoxide Hydrolase

This disclosure relates to methods of reducing inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH)....

Full description

Saved in:
Bibliographic Details
Main Authors Lee, Kin Sing Stephen, Connor, Kip M, Hammock, Bruce D, Hasegawa, Eiichi
Format Patent
LanguageEnglish
Published 15.11.2018
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:This disclosure relates to methods of reducing inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH). This disclosure also relates to methods of treating disorders associated with inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH). This disclosure further relates to pharmaceutical compositions and kits comprising at least one stable analog of CYP450 lipid metabolites (e.g., eicosanoids) and at least one inhibitor of a soluble epoxide hydrolase (sEH).
Bibliography:Application Number: US201615777141